MedTrace Logo

OPTIMISE Lung SABR

NCT07777614 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 208

Last updated 2026-08-20

No results posted yet for this study

Summary

This study is a phase II multi-centre, randomised study independently evaluating five fraction Image-Guided Stereotactic Ablative Radiotherapy (IG-SABR) and three fraction IG-SABR for patients with a peripherally located T1-T2 and selected T3 and T4 lung tumours, or a peripherally located single pulmonary oligometastatic lesion.

Conditions

  • Non Small Cell Lung Cancer

Interventions

RADIATION

Five fraction Image-guided Stereotactic Ablative Radiotherapy (IG-SABR) treatment

IG-SABR using a total of 5 fractions (12 Gy per fraction) to a total dose of 60 Gy prescribed to 95% of the Planning Target Volume (PTV).

RADIATION

Investigational three fraction image-guided Stereotactic Ablative Radiotherapy (IG-SABR)

IG-SABR using a total of 3 fractions (18 Gy per fraction) to a total dose of 54 Gy prescribed to 99% of the Gross Tumour Volume (GTV) with a minimum dose of 49.7 Gy to 95% of the Planning Tumour Volume (PTV) and 48 Gy to 99% of the PTV (i.e. 'optimised' three fraction SABR)

Sponsors & Collaborators

  • Focas Research Institute, Technological University Dublin

    collaborator UNKNOWN

  • Cancer Trials Ireland

    lead NETWORK

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-10-31
Primary Completion
2029-12-31
Completion
2035-06-30

Countries

  • Ireland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07777614 on ClinicalTrials.gov